Bibliography
- Schellekens H. Biosimilar therapeutics – what do we need to consider? NDT Plus 2009;10(Suppl 1):i27-36
- Roger SD, Mikhail A. Biosimilars: opportunity or cause for concern? J Pharm Pharmaceut Sci 2007;10:405-10
- Ben-Maimon CS. Point: why biogenerics make sense. Nat Biotechnol 2006;24:268-9
- Covic A, Cannata-Andia J, Cancarini G, Biosimilars and biopharmaceuticals: what nephrologists need to know – a position paper by the ERA-EDTA Council. Nephrol Dial Transplant 2008;23:3731-7
- Roger SD. Biosimilars: how similar or dissimilar are they? Nephrology 2006;11:341-6
- Storring PL, Tiplady RJ, Gaines Das RE, Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties. Br J Haematol 1998;100:79-89
- Chirino AJ, Mire-Sluis A. Characterizing biological products and assessing comparability following manufacturing changes. Nat Biotechnol 2004;22:1383-91
- Brockmeyer C, Seidl A. Binocrit: assessment of quality, safety and efficacy of biopharmaceuticals. EJHP Practice 2009;15:34-40
- Guideline on similar biological medicinal products. European Medicines Agency London, UK, 2005: Available from: http://www.emea.europa.eu/pdfs/human/biosimilar/043704en.pdf [Last accessed 29 March 2010]
- European Pharmacopoeia 6.0 (06/2007:1316). Strasbourg, France: European Directorate for the Quality of Medicines and Healthcare, 2007: Available from: http://www.edqm.eu/site/The_European_Pharmacoppeia_6th_ Edition-681.html [Last accessed 29 March 2010]
- Kessler M, Goldsmith D, Schellekens H. Immunogenicity of biopharmaceuticals. Nephrol Dial Transplant 2006;21(Suppl 5):v9-12
- Schellekens H. Immunologic mechanisms of EPO-associated pure red cell aplasia. Best Pract Res Clin Haematol 2005;18:473-80
- Sorensen PS, Ross C, Clemmesen KM, Clinical importance of neutralising antibodies against interferon beta in patients with relapsing remitting multiple sclerosis. Lancet 2003;362:1184-91
- Schellekens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther 2002;24:1720-40
- Schellekens H, Casadevall N. Immunogenicity of recombinant human proteins: causes and consequences. J Neurol 2004;251(Suppl 2):II4-9
- Hartung HP, Munschauer FR III, Schellekens H. Significance of neutralizing antibodies to interferon beta during treatment of multiple sclerosis: expert opinions based on the Proceedings of an International Consensus Conference. Eur J Neurol 2005;12:588-601
- Pollock C, Johnson DW, Hörl WH, Pure red cell aplasia induced by erythropoiesis-stimulating agents. Clin J Am Soc Nephrol 2008;3:193-9
- Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues. London, UK: European Medicines Agency, 2006. Available from: http://www.emea.europa.eu/pdfs/human/biosimilar/4934805en.pdf [Last accessed 29 March 2010]
- Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. London, UK: European Medicines Agency. 2006. Available from: http://www.emea.europa.eu/pdfs/human/biosimilar/4283205en.pdf [Last accessed 29 March 2010]
- Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins. London, UK: European Medicines Agency, 2007: Available from: http://www.emea.europa.eu/pdfs/human/biosimilar/1432706enfin.pdf [Last accessed 29 March 2010]
- Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. Guidance on similar medicinal products containing recombinant erythropoietins. London, UK: European Medicines Agency, 2006. Available from: http://www.emea.europa.eu/pdfs/human/biosimilar/9452605en.pdf [Last accessed 29 March 2010]
- Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. Guidance on similar medicinal products containing somatropin. London, UK: European Medicines Agency, 2006. Available from: http://www.emea.europa.eu/pdfs/human/biosimilar/9452805en.pdf
- Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. Guidance on similar medicinal products containing recombinant granulocyte-colony stimulating factor (G-CSF). London, UK: European Medicines Agency, 2006. Available from: http://www.emea.europa.eu/pdfs/human/biosimilar/3132905en.pdf [Last accessed 29 March 2010]
- Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. Guidance on similar medicinal products containing recombinant human insulin. London, UK: European Medicines Agency, 2006. Available at: http://www.emea.europa.eu/pdfs/human/biosimilar/3277505en.pdf [Last accessed 29 March 2010]
- Non-clinical and clinical development of similar medicinal products containing recombinant interferon alfa. London, UK: European Medicines Agency, 2009. Available from: http://www.emea.europa.eu/pdfs/human/biosimilar/10204606enfin.pdf [Last accessed 29 March 2010]
- Guideline on non-clinical and clinical development of similar biological medicinal products containing low-molecular-weight-heparins. London, UK: European Medicines Agency, 2009. Available from: http://www.emea.europa.eu/pdfs/human/biosimilar/11826407enfin.pdf [Last accessed 29 March 2010]
- US House Panel Backs Exclusivity for Biologic Drugs. New York, NY: August 1 2009. Available from: http://online.wsj.com/article/SB124917341780899303.html [Accessed 7 April 2010]
- Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues. Woden, Australia, Therapeutic Goods Administration: 2003. Available from: http://www.tga.gov.au/docs/html/euguide/euad_bio.html [Last accessed 7 April 2010]
- EU guideline – as adopted in Australia by the TGA – with amendment – guideline on comparability of medicinal products containing biotechnology derived proteins as active substance: non-clinical and clinical issues. Woden, Australia, Therapeutic Goods Administration: 2005. Available from: http://www.tga.gov.au/docs/pdf/euguide/bmwp/4283205en.pdf[s3] [Last accessed 29 March 2010]
- Consultation on the Regulatory Framework for Subsequent Entry Biologics – Summary Report. Aylmer, Quebec, Canada: Health Canada, 2008. Available from: http://www.hc-sc.gc.ca/dhp-mps/pubs/biolog/2008-consult-seb-pbu-rep-rap/index-eng.php [Last accessed 29 March 2010]
- Roger SD, Goldsmith D. Biosimilars: it's not as simple as cost alone. J Clin Pharm Ther 2008;33:459-64
- Questions and answers on recommendation for refusal of marketing application for Alpheon. London, UK: European Medicines Agency, 2006. Available from: http://www.emea.europa.eu/pdfs/ human/opinion/19089606en.pdf [Last accessed 29 March 2010]
- Questions and answers on the withdrawal of the marketing authorisation application for Insulin Human Rapid Marvel Insulin Human Long Marvel Insulin Human 30/70 Mix Marvel. London, UK, European Medicines Agency, 2008. Available from: http://www.ema.europa.eu/humandocs/PDFs/EPAR/insulinhumanrapidmarvel/419308en.pdf [Last accessed 29 March 2010]
- Withdrawal assessment report for Insulin Human Rapid Marvel international nonproprietary name: soluble insulin injection, Procedure No. EMEA/H/C/845 London, UK, European Medicines Agency, 2008. Available from: http://www.ema.europa.eu/humandocs/PDFs/EPAR/insulinhumanrapidmarvel/31777807en.pdf [Last accessed 29 March 2010]
- Citizen's Petition Supplement No. 3 (03P-0064), Rockvile, MD: Federal Drug Administration. 2004. Available from: http://www.fda.gov/OHRMS/DOCKETS/dailys/04/oct04/101504/03p-0064-rc00001-01-vol5.pdf [Last accessed 29 March 2010]
- PhRMA. Medicines in development: Biotechnology. 2006 report. Available from: http://www.phrma.org/files/attachments/Biotech%202006.pdf [Accessed 7 April 2010]
- Wildt S, Gerngross T. The humanization of N-glycosylation pathways in yeast. Nat Rev Microbiol 2005;3:119-28
- Rossert J, Casadevall N, Eckardt KU. Anti-erythropoietin antibodies and pure red cell aplasia. J Am Soc Nephrol 2004;15:398-406
- Bennett CL, Luminari S, Nissenson AR, Pure red-cell aplasia and epoetin therapy. N Engl J Med 2004;351:1385-7
- Macdougall IC. Biosimilar epoetins. Nephrol Dial Transplant 2009;24:1698-9
- Krivoshiev S, Todorov VV, Manitius J, Comparison of the therapeutic effects of epoetin zeta and epoetin alpha in the correction of renal anaemia. Curr Med Res Opin 2008;24:1407-15
- Kaufman JS, Reda DJ, Fye CL, Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. N Engl J Med 1998;339:578-83